Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Xoft Installs Axxent Electronic Brachytherapy At New Sites

Xoft, a developer of Axxent Electronic Brachytherapy, eBx System, which delivers non-radioactive, electronic radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, has reported 10 new installations of the Axxent eBx System for the treatment of skin cancer.

Xoft claimed that since the launch of skin and surface applicator, more than 100 skin cancer patients have been treated using the eBx technology. At many sites, the eBx systems are being used to clinically treat patients for breast, endometrial and skin cancer.

Xoft said that in addition to skin indications, the system is also FDA cleared for surface indications, which means that many intraoperative radiation therapy procedures can be performed with the Xoft source, while surgery is being performed. IORT potentially reduces the time required for radiation therapy by delivering it immediately during surgery before any remaining cancer cells have a chance to grow.

Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx System is also FDA-cleared for IORT (intra-operative radiation therapy). As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.

Utilizing a miniaturized X-ray source and robotic controller, the system can be used to deliver radiation in minimally shielded therapeutic settings. Treatment can be performed without the need for a shielded room, allowing radiation oncologists and medical personnel to be present during treatment which minimizes patient anxiety.

Michael Klein, president and CEO of Xoft, said: “With minimal radiation exposure to healthy tissues and rapid dose fall-off, Electronic Brachytherapy delivers targeted treatment that is professionally validated and patient friendly. When eBx was first introduced as an X-ray-based, electronic treatment option for early stage breast cancer, it represented a paradigm shifting technology, supporting the development of a suite of interventional radiation oncology tools.

“As we have launched additional applications and indications, we are pleased with the strong support and rapid adoption of these multi-disciplinary approaches for use of Electronic Brachytherapy to deliver safe, targeted treatment.”